Steroid cell tumour of the ovary: a case report with review of literature

Fathima Seles M., M. Revathy, Madurai Padmanabhan Kanchana*

Institute of Obstetrics and Gynecology, Madras Medical College, Chennai, Tamil Nadu, India

Received: 12 June 2018
Accepted: 05 July 2018

*Correspondence:
Dr. Madurai Padmanabhan Kanchana,
E-mail: mpkanchana@rediffmail.com

ABSTRACT

Virilising ovarian tumours account for less than 5% of all ovarian tumours. A steroid cell tumour (SCTs) of the ovary comes under the sex cord stromal tumours and accounts for only 0.1% of all ovarian tumours. Almost 75% are functioning tumors with production of androgenic hormones causing virilisation and cushingoid features. They are usually unilateral, benign with only 25-45% malignant cases. Here authors report the incidence of steroid cell tumour in our institution and discuss about a 37-year-old woman with steroid cell tumour, not otherwise specified who presented with oligomenorrhea followed by amenorrhea, secondary infertility and signs of virilisation.

Keywords: Androgen secreting tumours, Hirsutism, Ovary, Steroid cell tumour, Virilisation, Virilising ovarian tumours

INTRODUCTION

Steroid cell tumours of the ovary are a rare type sex cord stromal tumours, accounting for less than 0.1% of all ovarian tumours. Virilizing ovarian tumours account for less than 5% of all ovarian tumours. 

Steroid cell tumours produce steroids especially testosterone and generally show androgenic symptoms like amenorrhea, abnormal hair growth in the face and body, hair loss, deepening of voice and increased libido.

According to the WHO, the androgen secreting steroid cell tumours are further classified as either pure sertoli, sertoli-Leydig, gynandroblastomas, or steroid cell, NOS, wherein steroid cell, NOS is the most common type accounting for approximately 60% of steroid cell tumours.

Historically these tumours have been referred to as lipoid cell tumours, lipid cell tumours, luteomas, masculinovblastomas, hypernephroid tumours, adrenal-like tumours and adrenal rest tumours, since the exact lineage of the tumour is not known.

Initially, Morris and Scully described these tumors as ovarian epithelial tumours with functioning stroma. Later in 1979, term Steroid cell tumour, not otherwise specified was coined by Scully, signifies that cell lineage from which tumour arises is not known. Steroid cell tumours were historically designated as lipid cell tumour. However, there was no fatty component found in the tumor, so the name was changed into steroid cell tumour.

CASE REPORT

A 31-year-old woman presented with complaints of lower abdominal pain for one week, associated with two years of oligomenorrhea followed by four months of amenorrhea. She also gave history of secondary infertility for past 5 years. On examination patient was obese with frontal recession of hairline, temporal baldness, facial hair growth and grade II breast atrophy (Figure 1). Per abdomen examination was soft.
The patient showed signs of virilisation such as frontal recession of hairline, temporal baldness and facial hair.

Ultrasonogram (USG) scan abdomen showed hypoechoic mass lesion measuring 2.9x3 cm in the right ovary with profuse vascularity within and the remnant of normal ovary measured 3.7x2.4 cm. The radiological diagnosis of malignant ovarian tumour was given. Computed Tomography (CT) scan abdomen showed a well-defined irregular cystic space occupying lesion with evidence of peripheral soft tissue density nodule seen in the right ovary measuring 6x4x3 cm. The enhancing round nodule measured 2.4x3x2.4 cm and diagnosis of cystadenoma nature was rendered.

Serum tumour marker levels were within the normal range. CA 125-5.8 IU/ml. Serum LDH-149 IU/L. Serum AFP-1.22ng/ml. Serum Beta HCG-undetectable. Serum testosterone was elevated (>200 ng/dL). Thyroid function tests were normal.

Laparotomy was performed under general anesthesia and was proceeded to right salpingo-oophorectomy. Right ovary showed a well encapsulated cystic mass measuring 3.5x4 cm. The specimen was sent for frozen section which showed features suggestive of steroid cell tumour of ovary. In view of fertility issues, the procedure was ended with right salpingo-oophorectomy.

Macroscopically, the right ovary measured 4.5x3.5x2 cm with attached tube measured 4.5 cm in length. External surface was homogenous white, soft in consistency with smooth surface. Cut surface of ovary showed a well circumscribed, solid orange yellow mass measuring 1.5 cm in diameter (Figure 2). 5ml of peritoneal aspirate fluid was sent for cytological analysis.

Serum tumour marker levels were within the normal range. CA 125-5.8 IU/ml. Serum LDH-149 IU/L. Serum AFP-1.22ng/ml. Serum Beta HCG-undetectable. Serum testosterone was elevated (>200 ng/dL). Thyroid function tests were normal.

Laparotomy was performed under general anesthesia and was proceeded to right salpingo-oophorectomy. Right ovary showed a well encapsulated cystic mass measuring 3.5x4 cm. The specimen was sent for frozen section which showed features suggestive of steroid cell tumour of ovary. In view of fertility issues, the procedure was ended with right salpingo-oophorectomy.

Microscopically, the tumour showed a neoplasm arranged in sheets composed of round to polygonal cells with clear vacuolated cytoplasm and centrally placed nuclei. There was no atypia, mitosis nor necrosis. Delicate fibrovascular septa was seen in between the cell clusters. The surrounding parenchyma showed stromal hyperplasia. Tube showed no significant pathology (Figures 3 and 4). Peritoneal aspirate fluid was negative for malignant cells.

DISCUSSION

Over a span of five years from May 2013 to April 2018, 773 patients underwent ovarian mass excision in present institution, a tertiary care gynecological centre.
Out of which 157 were non-neoplastic, 340 were benign, 34 were borderline and 214 were malignant.

Only one case of steroid cell tumour of ovary was reported during that period, which accounted for 0.17% of all the ovarian neoplasms reported and 0.29% of all the benign tumours in the ovary (Figure 5).

Steroid cell tumours are grouped under sex cord stromal tumours, and they are usually unilateral, benign in nature and formed by proliferation of steroid cells.1 Steroid cell tumours generally show androgenic symptoms like amenorrhea, abnormal hair growth in the face and body, hair loss, deepening of voice and increased libido.1,3

Steroid cell tumours of the ovary are identified based on the absence of pathognomonic features, seen in other androgen secreting ovarian tumours such as Reinke crystals, Call-Exner bodies, and prominent nucleoli.4 Typically, a menstruating female will first notice oligomenorrhea followed by amenorrhea.10

The small solid ovarian tumours can be detected by carefully assessing the texture of the ovary using gray-scale ultrasonography. The tumour area is well demarcated by the different echogenicities.11 Serum testosterone level above 200 ng/dL is of diagnostic significance to identify androgen secreting tumours.12

Steroid cell tumours are divided into three subtypes according to their cell of origin: stromal luteoma arising from ovarian stroma, Leydig cell tumour arising from Leydig cells and steroid cell tumour not otherwise specified (NOS) when the lineage of the tumour is unknown.13,14

Macroscopically steroid cell tumours are often yellow-orange, reflecting their high lipid content, with hemorrhagic and cystic areas rarely seen.15 The tumour is usually confined to the ovary, but few cases with extra-ovarian steroid cell tumour have been reported.16

These tumours may cause isosexual precocious puberty in children and virilisation in adults, such as hirsutism, temporal alopecia, atrophy of breast, clitoromegaly and oligomenorrhea/amenorrhea.17

Microscopically, the neoplastic cells have abundant clear vacuolated cytoplasm with rich vascularity, and absence of atypia or necrosis.18 Inhibin is positive in 5%-90% of the cases and EMA is always negative.19

Metastasis occurs even in 20% of the benign cases, usually within the abdominal cavity and rarely to distant sites.20 Steroid cell tumours are generally benign; Hayes and Scully identified the following microscopic features that are associated with malignancy.20,21

Table 1: Microscopic features associated with malignancy.

<table>
<thead>
<tr>
<th>Microscopic features</th>
<th>% chance of malignancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two or more mitotic figures per 10 high-power fields</td>
<td>92</td>
</tr>
<tr>
<td>Necrosis</td>
<td>86</td>
</tr>
<tr>
<td>Size of 7 cm or larger</td>
<td>78</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>77</td>
</tr>
<tr>
<td>Grade 2/3 nuclear atypia</td>
<td>64</td>
</tr>
</tbody>
</table>

The management for sex cord stromal cell tumours is surgical removal of the tumour. Steroid cell tumour NOS, in young patients may be treated by unilateral oophorectomy. However close surveillance of child bearing women undergoing unilateral oophorectomy is necessary because there is 5% possibility of contralateral involvement.4 If the patient has completed the family; hysterectomy, removal of the contralateral ovary and complete surgical staging are recommended.4

CONCLUSION

Steroid cell tumours, NOS, are usually rare tumours. Proper history and physical examination, in addition to laboratory values and imaging studies helps in arriving at the diagnosis. Disease management should be decided based on tumour pathology, surgical staging and the desire for preserving fertility. The primary treatment is surgical removal of the primary lesion, and radiation or chemotherapy is not much effective.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES


